Literature DB >> 2095346

Enhanced elimination of piroxicam by administration of activated charcoal or cholestyramine.

D G Ferry1, L R Gazeley, W J Busby, D M Beasley, I R Edwards, A J Campbell.   

Abstract

This study has compared the effect of repeated administration of charcoal and cholestyramine on the elimination of piroxicam. Eight young adults were given piroxicam as a single dose of 20 mg, on 3 separate occasions. On one of the occasions charcoal was also given. On another occasion cholestyramine was also administered. The mean elimination half-life after piroxicam alone was 53.1 h. This was reduced to 40.0 h by charcoal administration and to 29.6 h after administration of cholestyramine. In the second phase of the study 7 elderly subjects received piroxicam 20 mg for 14 days on two occasions. Cholestyramine administration at the end of one of the periods reduced the mean elimination half-life of piroxicam from 52.3 h to 27.3 h.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2095346     DOI: 10.1007/bf00316105

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Oral cholestyramine increases elimination of warfarin after overdose.

Authors:  S Renowden; D Westmoreland; J P White; P A Routledge
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-24

2.  Clinical pharmacokinetics of piroxicam.

Authors:  R K Verbeeck; C J Richardson; K L Blocka
Journal:  J Rheumatol       Date:  1986-08       Impact factor: 4.666

Review 3.  Clinical pharmacokinetics of oral activated charcoal in acute intoxications.

Authors:  P J Neuvonen
Journal:  Clin Pharmacokinet       Date:  1982 Nov-Dec       Impact factor: 6.447

4.  Cholestyramine resin in the treatment of digitoxin toxicity.

Authors:  A M Baciewicz; M L Isaacson; G L Lipscomb
Journal:  Drug Intell Clin Pharm       Date:  1983-01

Review 5.  Enhancement of xenobiotic elimination: role of intestinal excretion.

Authors:  Z H Israili; P G Dayton
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

6.  The steady-state pharmacokinetics of piroxicam: effect of food and iron.

Authors:  W J Tilstone; D H Lawson; F Omara; F Cunningham
Journal:  Eur J Rheumatol Inflamm       Date:  1981

7.  Comparative steady state pharmacokinetic study of piroxicam and flurbiprofen in normal subjects.

Authors:  H J Rogers; R G Spector; P J Morrison; I D Bradbrook
Journal:  Eur J Rheumatol Inflamm       Date:  1981

8.  Analysis of piroxicam in plasma by high-performance liquid chromatography.

Authors:  T M Twomey; S R Bartolucci; D C Hobbs
Journal:  J Chromatogr       Date:  1980-07-11

9.  Effect of oral charcoal and urine pH on dextropropoxyphene pharmacokinetics.

Authors:  S Kärkkäinen; P J Neuvonen
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1985-04

10.  The influence of cholestyramine on the elimination of tenoxicam and piroxicam.

Authors:  T W Guentert; R Defoin; H Mosberg
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more
  3 in total

1.  Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism.

Authors:  Chang-Keun Cho; Pureum Kang; Hye-Jung Park; Eunvin Ko; Chou Yen Mu; Yun Jeong Lee; Chang-Ik Choi; Hyung Sik Kim; Choon-Gon Jang; Jung-Woo Bae; Seok-Yong Lee
Journal:  Arch Pharm Res       Date:  2022-05-31       Impact factor: 4.946

Review 2.  Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.

Authors:  K T Olkkola; A V Brunetto; M J Mattila
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

3.  Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.

Authors:  Xiaoli Wang; Sabiha Mondal; Jessie Wang; Giridhar Tirucherai; Donglu Zhang; Rebecca A Boyd; Charles Frost
Journal:  Am J Cardiovasc Drugs       Date:  2014-04       Impact factor: 3.571

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.